Golimumab

Dimitrios A. Pappas; Joan M. Bathon; Delphine Hanicq; Uma Yasothan; Peter Kirkpatrick

doi:10.1038/nrd2982

Golimumab

Dimitrios A. Pappas, Joan M. Bathon, Delphine Hanicq, Uma Yasothan, Peter Kirkpatrick

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.

Original language	English (US)
Pages (from-to)	695-696
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	8
Issue number	9
DOIs	https://doi.org/10.1038/nrd2982
State	Published - 2009
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd2982

Cite this

@article{3d37d1d9adaa45d9a3a1de2dd874238c,

title = "Golimumab",

abstract = "Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.",

author = "Pappas, {Dimitrios A.} and Bathon, {Joan M.} and Delphine Hanicq and Uma Yasothan and Peter Kirkpatrick",

year = "2009",

doi = "10.1038/nrd2982",

language = "English (US)",

volume = "8",

pages = "695--696",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Golimumab

AU - Pappas, Dimitrios A.

AU - Bathon, Joan M.

AU - Hanicq, Delphine

AU - Yasothan, Uma

AU - Kirkpatrick, Peter

PY - 2009

Y1 - 2009

N2 - Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.

AB - Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.

UR - http://www.scopus.com/inward/record.url?scp=69949182414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949182414&partnerID=8YFLogxK

U2 - 10.1038/nrd2982

DO - 10.1038/nrd2982

M3 - Article

C2 - 19721444

AN - SCOPUS:69949182414

SN - 1474-1776

VL - 8

SP - 695

EP - 696

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 9

ER -

Golimumab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this